8-K: bioAffinity Secures Key Lung Cancer Diagnostic Patent

bioAffinity Technologies announced a U.S. patent allowance for its AI-driven CyPath Lung diagnostic, enhancing its intellectual property for early-stage lung cancer detection.

Summary

• bioAffinity Technologies, Inc. received a notification of allowance from the United States Patent and Trademark Office (USPTO) for a new patent.
• The patent is titled 'Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning'.
• It covers a system and method for predicting the likelihood of lung cancer by analyzing patient sputum samples.
• The technology utilizes an AI-built algorithm and flow cytometry platform to analyze cell populations in sputum.
• CyPath Lung, the company's commercially available test, detects changes in the lung linked to cancer, including immune cells, apoptotic cells, and cancer/cancer-related cells labeled by proprietary TCPP porphyrin.
• The AI-driven analysis combines these variables with patient age to predict lung cancer.
• Clinical study results for CyPath Lung demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small lung nodules (less than 20 millimeters).
• The company's global patent estate now includes 18 awarded and 33 pending patents across multiple countries including the U.S., Canada, China, France, Germany, Hong Kong, Italy, Japan, Mexico, Spain, Sweden, and the United Kingdom.

Sentiment

Score: 8

Explanation: The allowance of a key patent for its core diagnostic technology is a significant positive development for bioAffinity Technologies, validating its innovation and strengthening its market position in early-stage lung cancer detection.

Positives

• Receipt of a U.S. patent allowance strengthens intellectual property protection for the company's core diagnostic technology.
• The patent validates the innovative AI-built algorithm and flow cytometry platform used in CyPath Lung.
• CyPath Lung demonstrates high performance metrics with 92% sensitivity, 87% specificity, and 88% accuracy in detecting early-stage lung cancer.
• The diagnostic is noninvasive, designed to alleviate patient anxiety, prevent unnecessary invasive procedures, and reduce healthcare system costs.
• The expanding global patent portfolio, now with 18 awarded and 33 pending patents, indicates strong intellectual property growth and market protection.

Risks

• The benefits to be derived from the patent may not materialize as expected.
• The company's ability to effectively safeguard its intellectual property against infringement or challenges.
• The effectiveness of its AI-based technology in real-world clinical settings may vary.
• The ability of CyPath Lung to consistently and reliably identify lung cancer across diverse patient populations.

Future Outlook

The company believes its AI-driven diagnostic can detect lung cancer at its earliest Stage 1A, a potentially curative stage, and aims to improve outcomes and increase patient survival through early diagnosis and treatment. The newly allowed U.S. patent is expected to complement its expanding global patent estate.

Management Comments

• Maria Zannes, President and CEO of bioAffinity Technologies, stated: 'Artificial intelligence was integral to the development of our CyPath Lung test and has resulted in the detection of lung cancer at its earliest Stage 1A, a potentially curative stage.'
• Maria Zannes also noted: 'Harnessing AI with our novel flow cytometry platform has resulted in a diagnostic that produces high-precision, standardized, data-driven results.'

Industry Context

This patent allowance positions bioAffinity Technologies favorably within the competitive landscape of cancer diagnostics, particularly for lung cancer, which remains the leading cause of cancer death. The integration of AI and non-invasive methods aligns with broader industry trends towards precision medicine, early detection, and reducing healthcare costs and patient burden.

Stakeholder Impact

• Shareholders: Increased value of intellectual property and potential for future revenue growth from a validated and protected diagnostic product.
• Patients: Access to a noninvasive, high-precision test for early-stage lung cancer, potentially leading to earlier diagnosis, improved outcomes, and reduced anxiety.
• Healthcare System: Potential for reduced costs by preventing unnecessary invasive procedures and facilitating earlier, more effective treatment.

Next Steps

• Continue to market CyPath Lung as a Laboratory Developed Test (LDT) through Precision Pathology Laboratory Services.
• Leverage the expanded patent protection to support commercialization and market penetration of CyPath Lung.

Key Dates

Recommendation

The allowance of a crucial U.S. patent for bioAffinity's AI-driven CyPath Lung diagnostic significantly de-risks the company's core technology and strengthens its competitive moat. This intellectual property protection is vital for a biotechnology firm, validating its innovation and enhancing its long-term market potential in the critical area of early-stage lung cancer detection. The high sensitivity, specificity, and accuracy demonstrated by CyPath Lung, combined with its non-invasive nature and potential for cost reduction in healthcare, position the company for future growth. This development provides a strong fundamental basis for a 'buy' recommendation, indicating increased confidence in the company's ability to capitalize on its technology.

Keywords

Lung Cancer, Diagnostic, Patent, Artificial Intelligence, Flow Cytometry, Sputum Test, Early-Stage Cancer, Biotechnology, CyPath Lung, Medical Device